Corvus Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview

Corvus Pharmaceuticals

24/03/2023 21:03

* Corvus Pharmaceuticals Inc  CRVS.OQ   CRVS.O  is expected
to show no change in quarterly revenue when it reports 
results on March 28. 
    * 
    * ​Refinitiv's mean analyst estimate for Corvus
Pharmaceuticals
Inc is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $3​, above​ its last closing price
of $0.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.16       -0.16      -0.32     Missed  -104.3
 Jun. 30 2022  -0.17       -0.18      -0.18     Met     -1.9
 Mar. 31 2022  -0.15       -0.15      -0.18     Missed  -17.4​
 Dec. 31 2021  -0.18       -0.19      -0.20     Missed  -6.7
 ​​Sep.        -0.24       -0.26      -0.24     Beat    6.5
 30 2021                                                
 Jun. 30 2021  -0.31       -0.32      -0.28     Beat    11.6​
 Mar. 31 2021  -0.31       -0.31      -0.34     Missed  -9.7
 Dec. 31 2020  -0.33       -0.32      -0.33     Missed  -2.3
 This summary was machine generated March 24 at 21:03 GMT.  All
figures in US dollars  unless otherwise stated